Here we go again. Wasn't it you that used to immediately jump to the defence of Mr. O with similar nonesense whenever I criticized his ridiculous predictions? Remind me, how did they pan out again? Still think your support was well placed? I suppose you do as you are the first to jump to the defence of others that make similarly inaccurate predictions? Never mind my motives, says more about yours imo?
all invested here have CHK,d (apologies for that) out Sareums website. Many other candidates in their extensive pipeline of future prospects are just put on hold temporarily whilst they concentrate on CHK1 Inhibitor CCT245737 in trials, Tyk2 and in my opinion the biggie the Aurora + FLT3 programme which is in preclinical stage but should enter trials soon with HMUBEC as our Chinese partners. The future is indeed bright for S(t)AR. :o) :o). Rampiness level of this post = 8/10. IMO.
Kobi, come on now. Come up with something from your extensive repertoire of well researched knowledge about SAR and not only i but many others on here would give you the time of day. You either don't, can't or won't do it, but still you choose again to make childish criticisms of others. You seemingly just can't help but vent your angst and be deliberately confrontational to those who can do this tirelessly and selflessly every day and week for the benefit of all on this bb. Must be just to suit your own agenda. Goalposts move, stuff invariably happens as timelines slip. It,s called life. Deal with it you sad person!. I think you are a wee rascal sir!. Thoth brings hope to the table, you bring zilch. Please smile. :o).
Sareum's CEO, Dr Tim Mitchell, commented: "We would like to thank Paul for his invaluable contribution to the company over the last 12 years. During his time with us Paul helped to define the direction and strategy of the Company which has allowed us build considerable value into our development programmes through their progression towards, and into, early clinical development.
"We welcome Stephen to the board, who brings with him a wealth of financial and industry experience which will be crucial to the business as we look towards the next stages of our transformation into a clinical-stage development company."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.